GlassScriptPhysician profile
Raszana Shoemaker
NPI 1386464519
$2,624.90
in general payments reported to CMS, 2019-2025
32 companies · $2,055 in 2025
The $2,055 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $570 · 2025: $2,055.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,426 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,425.91 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $417.62 | 2024-2025 | Erleada, Talvey, Rybrevant |
| Novartis Pharmaceuticals Corporation | $299.06 | 2024-2025 | |
| Seagen INC. | $198.99 | 2025 | |
| Daiichi Sankyo INC. | $188.25 | 2025 | Datroway, Enhertu |
| Pfizer INC. | $187.10 | 2024-2025 | |
| Astellas Pharma US INC | $147.12 | 2025 | Padcev |
| Merck Sharp & Dohme LLC | $121.88 | 2025 | Keytruda, Lynparza, Keytruda Qlex |
| Regeneron Healthcare Solutions, INC. | $98.40 | 2025 | Libtayo |
| Caris Mpi, INC. | $88.53 | 2025 | Mi Cancer Seek |
| Adc Therapeutics America, INC. | $81.21 | 2024-2025 | |
| Sobi, INC | $70.71 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.93 | 2024-2025 | Fruzaqla, Alunbrig |
| Eisai INC. | $65.44 | 2025 | |
| Novocure INC. | $54.46 | 2025 | Optune Lua (Novottf-200t) |
| Genentech USA, INC. | $52.31 | 2025 | Itovebi, Phesgo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $48.11 | 2025 | |
| Incyte Corporation | $47.16 | 2025 | Jakafi, Niktimvo |
| Lilly USA, LLC | $41.83 | 2025 | Verzenio, Jaypirca |
| Pharmacosmos Therapeutics INC. | $41.32 | 2024 | Cosela |
| Bayer Healthcare Pharmaceuticals INC. | $34.10 | 2024-2025 | |
| Beone Medicines USA, INC. | $31.64 | 2025 | Tevimbra |
| Janssen Pharmaceuticals, INC | $31.09 | 2024 | Xarelto |
| Exelixis INC. | $26.55 | 2025 | Cabometyx |
| Genzyme Corporation | $24.93 | 2024 | |
| Pharmaessentia USA Corporation | $24.51 | 2025 | Besremi |
| Recordati_rare_diseases_inc. | $23.41 | 2025 | Sylvant |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.34 | 2025 | |
| Adaptive Biotechnologies Corporation | $21.96 | 2025 | Clonoseq |
| Taiho Oncology, INC. | $21.94 | 2025 | |
| Stemline Therapeutics INC. | $16.80 | 2024 | Orserdu |
| Geron Corporation | $14.73 | 2025 | Rytelo |
| Myriad Genetic Laboratories, INC. | $14.47 | 2025 | Myrisk |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raszana Shoemaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.